Elicio Therapeutics Current Cash

The latest current cash for ELTX is $15M as of March 2026. That compares with $18M in the prior-year period — down 18.5% year over year. Investors often review this figure alongside Elicio Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ELTX's current cash moved from $18M to $15M — a 18.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Elicio Therapeutics's operating scale or balance-sheet position.

A current cash figure of $15M for ELTX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ELTX's current cash ($15M), review year-over-year change from $18M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.